ArticleJournal of the American Heart Association2025
Age-Related Outcomes of Valve-in-Valve Transcatheter Aortic Valve Replacement for Structural Valve Deterioration.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-Access Transfemoral TAVI with a Balloon Expandable Valve: Age-Stratified Analysis of Clinical Outcomes.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundValve-in-valve transcatheter aortic valve replacement (TAVR) is a recognized alternative for treating the structural valve deterioration of bioprosthetic valves. Recent guidelines and trials have expanded the indications for TAVR to include younger patients with structural valve deterioration. In this study, we aimed to examine the outcomes of valve-in-valve TAVR across different age groups to understand the age-related clinical outcomes of treating structural valve deterioration following surgical aortic valve replacement and TAVR. METHODS AND
resultsIn this retrospective study, we included patients who underwent valve-in-valve TAVR at our center. We compared procedural complications and clinical outcomes among patients <75 years of age (n=99), those 75 to 84 years of age (n=103), and those ≥85 years of age (n=71). Echocardiography and computed tomography were used for follow-up evaluations. This study included 273 patients and revealed a low in-hospital complication rate across all age groups. Although the 3-year risk of all-cause mortality was higher in patients >85 years of age, no significant differences in the incidence of stroke/transient ischemic attack were observed among age groups. All groups exhibited significant improvements in valve hemodynamics that persisted for 3 years. Although leaflet thrombosis assessed using computed tomography imaging 30 days post-TAVR was more prevalent in the older group, age was not an independent predictor of this outcome.
conclusionsValve-in-valve TAVR was associated with an increased 3-year mortality risk among older patients despite consistent hemodynamic benefits across all age groups. Age-related differences in leaflet thrombosis did not predict hypoattenuated leaflet thickening, indicating that further studies are necessary to elucidate its implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.